NASDAQ: MIRM
Mirum Pharmaceuticals Inc Stock

$45.27-0.30 (-0.66%)
Updated May 13, 2025
MIRM Price
$45.27
Fair Value Price
N/A
Market Cap
$2.24B
52 Week Low
$23.83
52 Week High
$54.23
P/E
-28.12x
P/B
9.61x
P/S
5.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$379.25M
Earnings
-$77.34M
Gross Margin
77.1%
Operating Margin
-16.24%
Profit Margin
-20.4%
Debt to Equity
1.96
Operating Cash Flow
-$7M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MIRM Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine MIRM's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
MIRM
Ranked
#51 of 453

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$46.39A
$7.82A
$60.81A
View Top Biotech Stocks

Be the first to know about important MIRM news, forecast changes, insider trades & much more!

MIRM News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MIRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MIRM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MIRM is poor value based on its book value relative to its share price (9.61x), compared to the US Biotechnology industry average (4.14x)
P/B vs Industry Valuation
MIRM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MIRM due diligence checks available for Premium users.

Valuation

MIRM price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-28.12x
Industry
-164.79x
Market
25.53x

MIRM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
9.61x
Industry
4.14x
MIRM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MIRM's financial health

Profit margin

Revenue
$111.6M
Net Income
-$14.7M
Profit Margin
-13.2%
MIRM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MIRM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$690.2M
Liabilities
$457.0M
Debt to equity
1.96
MIRM's short-term assets ($410.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRM's short-term assets ($410.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MIRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.0M
Investing
-$16.1M
Financing
$6.4M
MIRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MIRM vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
MIRMC$2.24B-0.66%-28.12x9.61x
XENEC$2.27B-17.43%-9.83x3.00x
IBRXC$2.22B+6.36%-4.65x-3.75x
VCELC$2.20B+2.32%872.80x7.44x
VCYTB$2.30B-4.71%68.16x1.92x

Mirum Pharmaceuticals Stock FAQ

What is Mirum Pharmaceuticals's quote symbol?

(NASDAQ: MIRM) Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol MIRM. Mirum Pharmaceuticals stock quotes can also be displayed as NASDAQ: MIRM.

If you're new to stock investing, here's how to buy Mirum Pharmaceuticals stock.

What is the 52 week high and low for Mirum Pharmaceuticals (NASDAQ: MIRM)?

(NASDAQ: MIRM) Mirum Pharmaceuticals's 52-week high was $54.23, and its 52-week low was $23.83. It is currently -16.53% from its 52-week high and 89.97% from its 52-week low.

How much is Mirum Pharmaceuticals stock worth today?

(NASDAQ: MIRM) Mirum Pharmaceuticals currently has 49,534,709 outstanding shares. With Mirum Pharmaceuticals stock trading at $45.27 per share, the total value of Mirum Pharmaceuticals stock (market capitalization) is $2.24B.

Mirum Pharmaceuticals stock was originally listed at a price of $13.21 in Jul 18, 2019. If you had invested in Mirum Pharmaceuticals stock at $13.21, your return over the last 5 years would have been 242.69%, for an annualized return of 27.93% (not including any dividends or dividend reinvestments).

How much is Mirum Pharmaceuticals's stock price per share?

(NASDAQ: MIRM) Mirum Pharmaceuticals stock price per share is $45.27 today (as of May 13, 2025).

What is Mirum Pharmaceuticals's Market Cap?

(NASDAQ: MIRM) Mirum Pharmaceuticals's market cap is $2.24B, as of May 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Mirum Pharmaceuticals's market cap is calculated by multiplying MIRM's current stock price of $45.27 by MIRM's total outstanding shares of 49,534,709.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.